vs
STANDARD BIOTOOLS INC.（LAB）与LCNB CORP（LCNB）财务数据对比。点击上方公司名可切换其他公司
LCNB CORP的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.9M vs $19.6M），LCNB CORP净利率更高（23.7% vs -177.4%，领先201.1%），LCNB CORP同比增速更快（5.1% vs -11.5%），LCNB CORP自由现金流更多（$33.4M vs $-23.1M），过去两年LCNB CORP的营收复合增速更高（15.7% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
LCNB集团是总部位于美国的金融控股公司，通过旗下附属国民银行开展业务，主要为俄亥俄州区域市场的个人消费者、中小企业及本地社区机构提供零售与商业银行产品、财富管理及保险相关服务。
LAB vs LCNB — 直观对比
营收规模更大
LCNB
是对方的1.2倍
$19.6M
营收增速更快
LCNB
高出16.6%
-11.5%
净利率更高
LCNB
高出201.1%
-177.4%
自由现金流更多
LCNB
多$56.5M
$-23.1M
两年增速更快
LCNB
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $23.9M |
| 净利润 | $-34.7M | $5.7M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 29.2% |
| 净利率 | -177.4% | 23.7% |
| 营收同比 | -11.5% | 5.1% |
| 净利润同比 | -28.8% | -7.6% |
| 每股收益（稀释后） | $-0.09 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABLCNB
| Q4 25 | — | $23.9M | ||
| Q3 25 | $19.6M | $23.8M | ||
| Q2 25 | $21.8M | $22.8M | ||
| Q1 25 | $40.8M | $21.5M | ||
| Q4 24 | — | $22.7M | ||
| Q3 24 | $22.1M | $21.4M | ||
| Q2 24 | $22.5M | $19.3M | ||
| Q1 24 | $45.5M | $17.8M |
净利润LABLCNB
| Q4 25 | — | $5.7M | ||
| Q3 25 | $-34.7M | $6.9M | ||
| Q2 25 | $-33.5M | $5.9M | ||
| Q1 25 | $-26.0M | $4.6M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | $-26.9M | $4.5M | ||
| Q2 24 | $-45.7M | $925.0K | ||
| Q1 24 | $-32.2M | $1.9M |
毛利率LABLCNB
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABLCNB
| Q4 25 | — | 29.2% | ||
| Q3 25 | -168.5% | 35.6% | ||
| Q2 25 | -118.1% | 31.6% | ||
| Q1 25 | -80.8% | 25.6% | ||
| Q4 24 | — | 32.9% | ||
| Q3 24 | -120.9% | 24.9% | ||
| Q2 24 | -134.5% | 4.9% | ||
| Q1 24 | -132.2% | 12.5% |
净利率LABLCNB
| Q4 25 | — | 23.7% | ||
| Q3 25 | -177.4% | 29.1% | ||
| Q2 25 | -153.7% | 26.0% | ||
| Q1 25 | -63.8% | 21.4% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | -122.0% | 21.2% | ||
| Q2 24 | -203.3% | 4.8% | ||
| Q1 24 | -70.6% | 10.7% |
每股收益（稀释后）LABLCNB
| Q4 25 | — | $0.40 | ||
| Q3 25 | $-0.09 | $0.49 | ||
| Q2 25 | $-0.09 | $0.41 | ||
| Q1 25 | $-0.07 | $0.33 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | $-0.07 | $0.31 | ||
| Q2 24 | $-0.12 | $0.07 | ||
| Q1 24 | $-0.27 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $21.6M |
| 总债务越低越好 | — | $104.4M |
| 股东权益账面价值 | $399.7M | $273.9M |
| 总资产 | $539.6M | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.38× |
8季度趋势，按日历期对齐
现金及短期投资LABLCNB
| Q4 25 | — | $21.6M | ||
| Q3 25 | $129.4M | $35.9M | ||
| Q2 25 | $158.6M | $49.8M | ||
| Q1 25 | $150.9M | $37.7M | ||
| Q4 24 | — | $35.7M | ||
| Q3 24 | $210.6M | $39.4M | ||
| Q2 24 | $269.8M | $34.9M | ||
| Q1 24 | $287.1M | $33.0M |
总债务LABLCNB
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | $55.2M | $155.7M | ||
| Q2 24 | $55.1M | $162.2M | ||
| Q1 24 | $55.0M | $162.6M |
股东权益LABLCNB
| Q4 25 | — | $273.9M | ||
| Q3 25 | $399.7M | $269.9M | ||
| Q2 25 | $424.5M | $263.5M | ||
| Q1 25 | $454.6M | $258.7M | ||
| Q4 24 | — | $253.0M | ||
| Q3 24 | $489.3M | $253.2M | ||
| Q2 24 | $510.3M | $245.2M | ||
| Q1 24 | $577.3M | $233.7M |
总资产LABLCNB
| Q4 25 | — | $2.2B | ||
| Q3 25 | $539.6M | $2.2B | ||
| Q2 25 | $557.0M | $2.3B | ||
| Q1 25 | $579.6M | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $681.5M | $2.3B | ||
| Q2 24 | $708.7M | $2.4B | ||
| Q1 24 | $777.7M | $2.3B |
负债/权益比LABLCNB
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 0.11× | 0.61× | ||
| Q2 24 | 0.11× | 0.66× | ||
| Q1 24 | 0.10× | 0.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $34.4M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $33.4M |
| 自由现金流率自由现金流/营收 | -118.1% | 140.2% |
| 资本支出强度资本支出/营收 | 4.5% | 4.0% |
| 现金转化率经营现金流/净利润 | — | 6.08× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $54.5M |
8季度趋势，按日历期对齐
经营现金流LABLCNB
| Q4 25 | — | $34.4M | ||
| Q3 25 | $-22.2M | $14.0M | ||
| Q2 25 | $-20.7M | $5.5M | ||
| Q1 25 | $-30.3M | $2.2M | ||
| Q4 24 | — | $93.2M | ||
| Q3 24 | $-27.9M | $11.9M | ||
| Q2 24 | $-39.0M | $54.9M | ||
| Q1 24 | $-62.5M | $-11.9M |
自由现金流LABLCNB
| Q4 25 | — | $33.4M | ||
| Q3 25 | $-23.1M | $13.7M | ||
| Q2 25 | $-22.6M | $5.2M | ||
| Q1 25 | $-35.3M | $2.1M | ||
| Q4 24 | — | $89.4M | ||
| Q3 24 | $-30.1M | $10.5M | ||
| Q2 24 | $-41.0M | $53.8M | ||
| Q1 24 | $-63.3M | $-12.8M |
自由现金流率LABLCNB
| Q4 25 | — | 140.2% | ||
| Q3 25 | -118.1% | 57.4% | ||
| Q2 25 | -103.6% | 23.0% | ||
| Q1 25 | -86.6% | 10.0% | ||
| Q4 24 | — | 394.0% | ||
| Q3 24 | -136.4% | 49.0% | ||
| Q2 24 | -182.2% | 278.6% | ||
| Q1 24 | -138.9% | -71.8% |
资本支出强度LABLCNB
| Q4 25 | — | 4.0% | ||
| Q3 25 | 4.5% | 1.3% | ||
| Q2 25 | 8.7% | 1.0% | ||
| Q1 25 | 12.4% | 0.3% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | 10.2% | 6.7% | ||
| Q2 24 | 8.6% | 5.9% | ||
| Q1 24 | 1.7% | 4.8% |
现金转化率LABLCNB
| Q4 25 | — | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 15.23× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | — | -6.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
LCNB
暂无分部数据
